glp 1 latest news Health insurer Cigna will stop covering GLP-1 weight loss drugs in its employee health plan 🚨 Big news for people

Description

BackgroundGlucagon-like peptide-1 receptor agonist (GLP-1RA) pharmaceutical interventions have advanced medical treatment for obesity, yet little is known ab...

on the healthcare industry.

GLP-1 drugs are changing how people shop for food, clothes, and more, creating a 'seismic shift' in retail.

Physiological Effects Semaglutide exerts its therapeutic benefits through multiple complementary mechanisms: Enhanced Insulin Secretion: Stimulates glucose-dependent insulin release from pancreatic beta cells, improving postprandial glucose control[3][4] Glucagon Suppression: Inhibits glucagon release, reducing hepatic glucose production and improving fasting blood glucose levels[3][4] Delayed Gastric Emptying: Slows the movement of food from the stomach to the small intestine, reducing postprandial glucose excursions and promoting satiety[4][5] Appetite Reduction: Directly affects the central nervous system to decrease food intake and energy consumption[4][5] Improved Metabolic Flexibility: Enhances the body's ability to switch between energy substrates based on availability[2] At the cellular level, semaglutide primarily operates through the AMPK (AMP-activated protein kinase) pathway, which regulates cellular energy homeostasis and improves insulin sensitivity